Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis

医学 肾脏疾病 肾功能 内科学 重症监护医学 危险系数 随机对照试验 荟萃分析 急性肾损伤 高钾血症 造影剂肾病 系统回顾 多药 临床试验 肾病科 梅德林 心肾综合症
作者
Fadi Alghzawi,Yousef Alghzawi,Leen Alhassan,Raghad Kiyyam
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
标识
DOI:10.1111/dom.71434
摘要

AIMS: No randomized trial has compared SGLT2 inhibitors with finerenone in chronic kidney disease (CKD) with Type 2 diabetes. We estimated their comparative cardiorenal efficacy and safety. MATERIALS AND METHODS: MEDLINE, Embase, CENTRAL and trial registries were searched from inception to August 2026 for placebo-controlled outcome trials. Hazard ratios (HRs) were pooled in a frequentist random-effects network meta-analysis, and the between-class contrast was derived indirectly through placebo. Risk of bias followed RoB 2 and certainty followed CINeMA. RESULTS: Ten trial datasets formed a star network without closed loops. Versus placebo, both classes reduced kidney function progression (SGLT2 inhibitors HR: 0.64, 95% CI: 0.56-0.73; finerenone 0.84, 0.77-0.92) and heart-failure hospitalization (0.61, 0.53-0.69; 0.78, 0.66-0.92). Indirectly, SGLT2 inhibitors were favoured for kidney function progression (0.76, 0.64-0.90) and heart-failure hospitalization (0.77, 0.63-0.95), with no significant difference for atherothrombotic events or mortality. The kidney contrast remained significant after excluding high-risk-of-bias datasets, restricting to dedicated CKD trials and applying a uniform endpoint; the heart-failure contrast did not persist in dedicated CKD trials. Finerenone increased hyperkalemia without increasing acute kidney injury. Certainty was low or very low for every between-class comparison. CONCLUSIONS: SGLT2 inhibitors and finerenone both provide cardiorenal protection and appear complementary rather than interchangeable. Indirect differences favouring SGLT2 inhibitors derive from a loop-free network with unverifiable transitivity and low certainty; they are hypothesis-generating and should not be used to rank the agents. Safety domains are not reported comparably across classes. TRIAL REGISTRATION: CRD420261439899.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
领导范儿的应助被linmenting采纳,获得10
刚刚
桐桐的应助被zsn采纳,获得30
1秒前
1秒前
1秒前
甜蜜念真完成签到,获得积分10
1秒前
陶醉的筮发布了新的文献求助10
2秒前
SciGPT的应助被Lu采纳,获得10
2秒前
AHMZI完成签到,获得积分10
2秒前
2秒前
2秒前
苏波发布了新的文献求助10
2秒前
乐乐发布了新的文献求助10
2秒前
华仔的应助被美少女战士采纳,获得10
3秒前
深情安青的应助被霁月采纳,获得10
3秒前
Mimo发布了新的文献求助10
3秒前
传奇3的应助被霁月采纳,获得10
3秒前
生姜完成签到,获得积分10
3秒前
雪轩完成签到,获得积分10
4秒前
时尚的满天完成签到,获得积分10
4秒前
4秒前
隆隆发布了新的文献求助10
4秒前
4秒前
龙龙发布了新的文献求助10
4秒前
故事的角色完成签到,获得积分10
4秒前
科研通AI6.4的应助被刘倩雯采纳,获得10
5秒前
渡人舟的应助被will采纳,获得10
5秒前
11发布了新的文献求助10
5秒前
5秒前
轻松的黄豆完成签到,获得积分10
5秒前
今后的应助被xiaomi采纳,获得10
5秒前
6秒前
浅帅完成签到,获得积分10
6秒前
6秒前
6秒前
tlrelax完成签到,获得积分20
7秒前
研友_VZG7GZ的应助被飞快的孱采纳,获得10
7秒前
lalalall发布了新的文献求助10
7秒前
Hello的应助被仰望采纳,获得10
8秒前
白夜发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971